鶹ýɫƬ

Journal News

Rare genetic mutation in Amish population linked to ‘bad’ cholesterol levels

Farah Aziz Annesha
May 28, 2024

Low-density lipoprotein, or LDL, is commonly called “bad” cholesterol since high levels of LDL contribute to a higher risk of coronary heart disease.

A recent study conducted on Amish people, who are unique for genetic studies due to their isolation from the general population, shows a direct association between a novel genetic mutation in the SORT1 gene and human LDL levels. SORT1 is a gene that encodes for the protein sortilin, which previous studies suggest might influence LDL levels. However, functional studies on the gene have so far led to contradictory results.

Researchers working on this study were invited to dinners in the homes of the Amish study participants.
Kelly Mitok
Researchers working on this study were invited to dinners in the homes of the Amish study participants.

In collaboration with , this new study led by Kelly Mitok and colleagues at the University of Wisconsin–Madison is the first to establish a direct link between the SORT1 gene and LDL cholesterol.

This discovery can be informative for doctors, especially those who practice precision or personalized medicine. Like clothing that is custom-made to fit a person according to their measurements, precision medicine aims to provide tailored treatments and preventive measures according to an individual’s unique genomic data, environment and lifestyle.

“Every discovery that is made, including ours, is being added continuously to a library of information about the effect each genetic mutation has on humans,” Mitok said. “So when a patient has a SORT1 gene mutation, the doctor can suggest preventive treatment to help reduce their risk of coronary heart disease, because now they know that this SORT1 mutation is linked to LDL levels.”

Working in , Mitok began her work on SORT1 by studying links between SORT1 mutations and Type 2 diabetes. However, progress has been slow with little result. Searching for a new focus, Attie and Mitok asked their colleagues at the Amish Research Clinic if they had found any links between SORT1 mutations and diabetes.
The genetic studies staff informed them of links between SORT1 and LDL-cholesterol.

The researchers collected blood samples from clinical trial participants at the Amish Research Clinic and then conducted whole exome sequencing on the samples. This DNA sequencing technique is used to locate mutations within the exomic, or coding, region of the genome. They also performed clinical lipid panels to measure LDL cholesterol levels. Mitok and her team analyzed these data sets, looking for conclusive evidence for any links between the two.

Their findings, reported in an in the Journal of Lipid Research, showed that one coding mutation in the SORT1gene, called K302E, led to higher levels of LDL cholesterol in the Amish. However, mice studies with this mutation showed contradictory results. An explanation for the contradiction could be due to the difference in metabolism between the two species. This invaluable study will be crucial in informing future research on SORT1gene and its effect on human LDL cholesterol.

Mitok traveled from the University of Wisconsin–Madison to the Old Order Amish community in Lancaster County, Pennsylvania, where she presented her team’s findings to researchers at the Amish Research Clinic and members of the Amish community. She also assisted a member of the clinic in going house to house to recruit Amish individuals to participate in the next clinical study.

“The most rewarding aspect was how this went beyond just getting some data for research,” Mitok said, “It was how the Amish community trusted us like family, inviting us to dinners at their homes and actively participating in the study. This is due to the strong personal connections that the founder and director of the Amish Research Program, Dr. Alan Shuldiner, built with the Amish community from the start.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Farah Aziz Annesha

Farah Aziz Annesha is an aspiring science writer. She recently graduated from Yonsei University Underwood International College with a B.S. in biotechnology and a B.A. in comparative literature.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.